Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06622031
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-30
Brief Title:
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Transjugular Intrahepatic Portosystemic Shunt Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma With Main Trunk Portal Vein Tumor Thrombus a Multicenter Phase II Study
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatocellular carcinoma HCC with main trunk portal vein tumor thrombus PVTT has poor prognosis The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension then the second is the tumor-caused death It is vital to prevent the portal hypertension by PVTT
Detailed Description:
Portal hypertension by main trunk portal vein tumor thrombus PVTT is a severe disease Patients usually die of gastrointestinal hemorrhage rather than tumor progression It is vital to prevent the portal hypertension Transjugular intrahepatic portosystemic shunt TIPS is an effective method to alleviate the portal pressure Then the risk of gastrointestinal hemorrhage is decreased which provides an opportunity for system therapy In this study the investigators explore the TIPS combined with Lenvatinib and PD-1 inhibitor for advanced hepatocellular carcinoma with main trunk portal vein tumor thrombus The investigators aim to add clinical evidence for this subtype of advanced HCC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None